Letrozole : Debates about locomotor and Cardiac abnormalities are over. Now letrozole alone can be used as ART tooLetrozoel reduces miscarriage rate than spont conception cycles: : Evidence is here :Ob/Gyn Updated
Wednesday, January 4, 2017
Letrozole does not increase the risk of adverse pregnancy or neonatal outcomes and major congenital anomalies in patients conceived by ARTs.
Letrozole Tablets
Letrozole is an oral non-steroidal aromatase inhibitor approved by US Food and Drug Administration ( FDA) for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Off-label it has been used for ovarian stimulation in assisted reproduction since 2001.
A recent retrospective cohort study published online November 7, 2016 in Journal of Human Reproduction concluded that “letrozole stimulation reduces the risk of miscarriage, with no increase in the risk of major congenital anomalies or adverse pregnancy or neonatal outcomes compared with natural cycles in women undergoing ART. Letrozole may thus be a safe option for mild ovarian stimulation.”
The study used data from Japanese national ART registry between 2011 to 2013. It included 3136 natural cycles and 792 letrozole-induced cycles with, fresh single embryo transfer resulting in clinical pregnancy were included in the analysis.
The data was analyzed for rates of ectopic pregnancy, miscarriage and stillbirths as main pregnancy outcomes while preterm delivery, low birth weight, small/large for gestational age and major congenital anomalies were neonatal outcomes of primary importance.
After multivariate logistic regression, it was seen that women who received letrozole had 37% lower odds of miscarriage (P < 0.001). both groups were comparable for rates of congenital malformations. (natural cycle 1.5% vs letrozole 1.9%, P = 0.52)
No difference in rates of congenital malformations seen when analyzed for in vitro fertilization or ICSI and early cleavage stage or blastocyst embryo transfer.
Letrozole debate is now over :: Jury are out! !!!! Assessed risk io Cong malformations associated with Letrozole induced pregancy was overrules by any subsequent studies!!! The allegation was false and unfortunately one such article was presented in American Society of Reproductive Medicine 2005 Conference. [1] in Risk Letrozole was associated with increased risks of birth defects and has been banned as ovulation induction in many countries including India since 2011, following reports of 2 studies citing increase incidences of congenital malformations (locomotor and cardiac abnormalities). One such study was presented at the American Society of Reproductive Medicine 2005 Conference. [1] [1] Biljan MM, Hemmings R, Brassard N, et al. The outcome of 150 babies following treatment with letrozole or letrozole and gonadotropins. Presented at the American Society for Reproductive Medicine 61st Annual Meeting; October 14-19, 2005; Montreal, Quebec. Abstract O-231
But, What subsequently happened?? Truth is truth: Such off-label use of Letrozole for ovarian stimulation was never illegal in USA and UK. It is still used as an ovulation induction agent in ARTs.. My dear member ,ow use of letrozole has surpassed CC for any reasons including the miscarriage rate but the added feather in its crown is Letrozole can be used in ART(Mini-IVF-- MOS -->minimal ovarian stimulation) .Sometimes it is combined with CC and or HMG as well at the discretion of ART specialists
No comments:
Post a Comment